






Study on the deriving of oHSV-1 candidate for an immunotherapeutic targeting to the ovarian cancer

Gencellmed Inc.

Disease area	Cancer
Product Type	Oncolytic herpes simplex virus 1
Indication	Ovarian cancer
Target	Epithelial Cell Adhesion Molecule (EpCAM)
Mechanism of Action	<div><ul style="list-style-type: none">Specific-targeting to tumor-associated antigens (TAAs) by binding to the bi-specific adapter and the chimeric gH (Cancer cell-specific infection)Induction of a systemic anticancer effect by boosting the immune system through cytokines directly expressed from oHSVCancer-selective viral genome replication (pTERT-ICP6) and neurovirulence-defeciency (LAT deletion and UL56 gene truncation)</div> <div><div><div>GCM SMART (Synthetic & Multi-Antigen Retargeting Technology)</div></div></div>
Competitiveness	<ul style="list-style-type: none">Most competitor products in clinical trials are attenuated to various degrees, obtaining cancer specificity through attenuation. A potential drawback of these attenuated oHSVs is their less efficient replication, leading to lower viral production. In sharp contrast, GCM oHSV-1 has been developed to retarget HSV tropism to EpCAM while preserving full lytic potential.GCM oHSV-1 exclusively infects EpCAM-expressing cells, selectively replicating in cancer cells and avoiding replication in normal cells, ensuring high level of safety.In addition, the insertion of cytokine genes induces a robust systemic antitumor immune response.
Development Stage	Pre-clinical
Route of Administration	Intratumoral, intravenous, and intraperitoneal administration
Key Data	<div><div><div>Anti-tumoral efficacy of GCM oHSV-1 (CDX IP tumor model, IP administration)</div></div><div><div>Abscopal Effect of GCM oHSV-1 by Immune Activation (Syngeneic mouse model, IT administration)</div></div><div><div>Safety & Biodistribution of GCM oHSV-1 (Immunocompetent mice, IV injection)</div></div><div><div>Neurotoxicity of GCM oHSV-1 (Immunocompetent mice, Intranasal & Corneal)</div></div></div>
IP	<div><ul style="list-style-type: none">Patent No. 10-2311895 / KoreaPatent No. 11,421,017 / United States</div> <div><ul style="list-style-type: none">Patent No. 10-2405246 / KoreaPatent No. 10-2418528 / Korea</div> <div><ul style="list-style-type: none">Patent No. 7460850 / Japan</div>